GARDP Strategy
2024-2028.
Replenishing the antibiotic pipeline.
GARDP’s 2024–2028 strategy aims to build a robust portfolio of antibiotic treatments for serious bacterial infections and sepsis and for sexually transmitted infections, while increasing access for the people most affected by antimicrobial resistance (AMR).
To do this, we reshape the traditional antibiotic research and development model by prioritizing public health impact, affordability, and equitable access. We not only support the development of novel antibiotics, we bring partners together, undertake research to align product development with public health needs, and provide hands-on support in countries where new treatments are needed most.
Integrated R&D and access
We factor sustainable access into every stage of antibiotic development, from scientific discovery and R&D, right through to the manufacturing, registration, and commercialization.
Collaboration and license agreements
We help de-risk antibiotic development and in return secure the rights to make the treatments available in high-burden regions that would otherwise be left behind.
Equal partnerships
We bring together public and private sector partners from the outset to combine expertise, resources and global reach to tackle AMR.
Our disease areas.
Our programmes prioritize serious bacterial infections and sepsis (including newborns) and sexually transmitted infections (with a focus on gonorrhoea), and target World Health Organization (WHO) priority pathogens that are responsible for particularly deadly and debilitating drug-resistant infections.
GARDP also targets populations who are disproportionately affected by drug resistance – including newborns, children and women, particularly in low- and middle-income countries (LMICs).
Serious bacterial infections
Serious bacterial infections are one of the leading causes of death for people in hospitals, which can also escalate to life-threatening complications like sepsis.
Neonatal sepsis
Newborns are particularly vulnerable to sepsis because their immune systems are underdeveloped.
Sexually transmitted infections
Some sexually transmitted infections, like gonorrhoea, are in danger of becoming untreatable again because of drug resistance.
GARDP’s integrated approach to R&D and access.
GARDP factors access into every stage of antibiotic development, from scientific discovery and R&D to access.
We engage
in carefully selected antibiotic drug development and access projects that tackle the most pressing public health needs.
We lead
the charge or play a complementary role in the drug development process to meet the unique demands of each project.
We are deeply
involved
in pharmaceutical and clinical development to ensure that every treatment we develop is safe, effective, affordable and suitable for use in diverse settings, including those with a high AMR burden and limited resources.
GARDP’s focus.
To protect people from the rise and spread of AMR, GARDP has developed a disease area strategy that focuses on three overarching criteria.
GARDP’s expanded portfolio.
In 2019, GARDP first pledged to deliver five new treatments by 2025. Today, we have built a portfolio of more than five treatments, developed disease area strategies, determined critical unmet needs and identified priority areas based on factors such as disease burden. We have also identified priority populations and geographies, signed critical licensing agreements and built powerful collaborations and partnerships.
The results of this push go well beyond five treatments, setting us on course to deliver critical solutions for serious bacterial infections, hard-to-treat Gram-negative bacteria, sexually transmitted infections, and treatments for both paediatric and adult populations. One of the treatments in our portfolio, zoliflodacin, has received regulatory approval by the US FDA in December 2025, underscoring the success of GARDP’s not-for-profit drug development model.
GARDP looks forward to many future projects and is continually identifying new areas of need, new compounds, and projects worthy of further investment.
2024-2028 funding need.
For the period 2024–2028, delivering on GARDP’s strategy is estimated to cost €220 million.
This covers activities to address immediate urgent public health needs for antibiotics, while also strengthening a sustainable ecosystem needed for antibiotic research, development and access to meet future global needs.
Resources
GARDP Estrategia
GARDP Estratégia
GARDP戦略計画
5 BY 25 report